Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDP-02 in Mildly to Moderately Active Crohn's Disease
NCT00655135Phase 2Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Feb 2000
- Primary completion
- Jun 2002
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of vedolizumab in Crohn's disease (3 arms), sponsored by Millennium Pharmaceuticals. Primary endpoint: Proportion of patients with a clinical response at Day 57. Started Feb 2000; status: completed.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00655135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00655135.